Trial Profile
N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 01 Jul 2008
Price :
$35
*
At a glance
- Drugs Ethyl eicosapentaenoic acid (Primary) ; Eicosapentaenoic acid
- Indications Atrial fibrillation
- Focus Therapeutic Use
- 01 Jul 2008 New trial record.